Cargando…

The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma

BACKGROUND: The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhi‐Yuan, Guo, Zhi‐Xing, Lu, Liang‐He, Mei, Jie, Lin, Wen‐Ping, Li, Shao‐Hua, Wei, Wei, Guo, Rong‐Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366089/
https://www.ncbi.nlm.nih.gov/pubmed/34212527
http://dx.doi.org/10.1002/cam4.4102
_version_ 1783738839071719424
author Chen, Zhi‐Yuan
Guo, Zhi‐Xing
Lu, Liang‐He
Mei, Jie
Lin, Wen‐Ping
Li, Shao‐Hua
Wei, Wei
Guo, Rong‐Ping
author_facet Chen, Zhi‐Yuan
Guo, Zhi‐Xing
Lu, Liang‐He
Mei, Jie
Lin, Wen‐Ping
Li, Shao‐Hua
Wei, Wei
Guo, Rong‐Ping
author_sort Chen, Zhi‐Yuan
collection PubMed
description BACKGROUND: The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA). METHODS: From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated. RESULTS: There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05). CONCLUSIONS: The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR.
format Online
Article
Text
id pubmed-8366089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83660892021-08-23 The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma Chen, Zhi‐Yuan Guo, Zhi‐Xing Lu, Liang‐He Mei, Jie Lin, Wen‐Ping Li, Shao‐Hua Wei, Wei Guo, Rong‐Ping Cancer Med Clinical Cancer Research BACKGROUND: The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA). METHODS: From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated. RESULTS: There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05). CONCLUSIONS: The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR. John Wiley and Sons Inc. 2021-07-01 /pmc/articles/PMC8366089/ /pubmed/34212527 http://dx.doi.org/10.1002/cam4.4102 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Chen, Zhi‐Yuan
Guo, Zhi‐Xing
Lu, Liang‐He
Mei, Jie
Lin, Wen‐Ping
Li, Shao‐Hua
Wei, Wei
Guo, Rong‐Ping
The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
title The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
title_full The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
title_fullStr The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
title_full_unstemmed The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
title_short The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
title_sort predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366089/
https://www.ncbi.nlm.nih.gov/pubmed/34212527
http://dx.doi.org/10.1002/cam4.4102
work_keys_str_mv AT chenzhiyuan thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT guozhixing thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT lulianghe thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT meijie thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT linwenping thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT lishaohua thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT weiwei thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT guorongping thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT chenzhiyuan predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT guozhixing predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT lulianghe predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT meijie predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT linwenping predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT lishaohua predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT weiwei predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma
AT guorongping predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma